Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of denosumab in pediatric osteogenesis imperfecta
2018-000550-21Phase 3Terminated
- Sponsor
- Amgen
- Start
- May 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of denosumab in osteogenesis imperfecta (OI), sponsored by Amgen. Primary endpoint: Long-term safety of denosumab. Started May 2018; status: terminated.
02
Drugs
denosumab
03
Conditions
osteogenesis imperfecta (OI)
Beyond the preview
Go deeper on 2018-000550-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000550-21.